Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has ranked #1 on Fast Company’s fourth annual list of Best Workplaces for Innovators.

The 2022 Best Workplaces for Innovators ranks 100 winners from a variety of industries, including computer science, biotech, consumer packaged goods, nonprofit, education, financial services, cybersecurity, engineering, diversity, sustainability, B2B, and consumer products and services. Approximately 1,500 applications were scored, and a panel of eight eminent judges has reviewed and endorsed the top 100 companies. The 2022 awards feature workplaces from around the world.

“It’s thrilling to be recognized as a top place to innovate in the year we are celebrating our 20^th anniversary. Innovation and Discovery is one of Alnylam’s cherished core values and has been at the heart of this Company from day one,” said Akshay Vaishnaw, M.D., Ph.D., President of Alnylam. “Alnylam was founded and built by innovators, and we take great pride in providing an environment that continues to nurture innovation and ‘out of the box’ thinking. After all, patients’ lives depend on it.”

“This year’s list of the Best Workplaces for Innovators recognizes organizations that have demonstrated a deep commitment to cultivating creativity across the board,” says Brendan Vaughan, editor-in-chief of Fast Company. “In the face of powerful headwinds, these leaders and teams continue to spur innovation.”

About RNAi

RNAi (RNA interference) is a natural cellular process of gene silencing that represents one of the most promising and rapidly advancing frontiers in biology and drug development today. Its discovery has been heralded as "a major scientific breakthrough that happens once every decade or so," and was recognized with the award of the 2006 Nobel Prize for Physiology or Medicine. By harnessing the natural biological process of RNAi occurring in our cells, a new class of medicines, known as RNAi therapeutics, is now a reality. Small interfering RNA (siRNA), the molecules that mediate RNAi and comprise Alnylam's RNAi therapeutic platform, function upstream of today’s medicines by potently silencing messenger RNA (mRNA) – the genetic precursors – that encode for disease-causing or disease pathway proteins, thus preventing them from being made. This is a revolutionary approach with the potential to transform the care of patients with genetic and other diseases.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and prevalent diseases with unmet need. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach yielding transformative medicines. Since its founding 20 years ago, Alnylam has led the RNAi Revolution and continues to deliver on a bold vision to turn scientific possibility into reality. Alnylam’s commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), AMVUTTRA™ (vutrisiran), and Leqvio® (inclisiran) being developed and commercialized by Alnylam’s partner, Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P5x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam, on LinkedIn, or on Instagram.

About Fast Company

Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at www.fastcompany.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005469/en/